Meta-analysis: COVID-19 diagnosis in chest CT—master key for radiologists

Abstract

Background COVID-19 was discovered in February in China. Due to the high prevalence of the disease, early detection and rapid isolation of patients are the vital points for controlling the outbreak. The purpose of this study was to determine the correct location of chest CT scan in the diagnosis of COVID-19. Main text The current study is a systematic review and meta-analysis. 2959 papers were found in all national and international databases. The study has been reported based on the PRISMA checklist. All analyses were done by CMA Ver. 2 software. The statistical analysis results show that the GGO observation level in the available shape was 46% in CT scan results, and the consolidation observation level in the general form was 33% in CT scan results. Pleural effusion was 7%, and linear opacity observation level was 24% in CT scan results in the general form. The CT scan test sensitivity level was gained 94.7%, and PCR test sensitivity level was achieved as 94.8%. This level was 89% in the early stage. Conclusion The chest CT has about 24% higher diagnostic sensitivity than the PCR test, in the early stage. GGO revealed a declining process and also indicates that GGO is an early symptom of the disease in CT scan. Linear opacity is the reason behind the initial dyspnea in coronavirus suffering patients referring to the medical centers. The extra-pulmonary lesions increase in the last stage of the disease that makes the patient’s worse.

Extrapulmonary CT Findings Predict In-Hospital Mortality in COVID-19. A Systematic Review and Meta-Analysis

“…So far, pleural effusion was found in 5% of patients in early stages and in 16% of patients in advanced stages [42]. Similarly, mediastinal lymphadenopathy was observed in 4% of patients in early stages and in 15% of patients in advanced stages [42]. The time dependence may be a potential confounder of the present analysis.…”

“…Pleural effusion and lymphadenopathy were more frequently identified in later disease stages [42]. So far, pleural effusion was found in 5% of patients in early stages and in 16% of patients in advanced stages [42]. Similarly, mediastinal lymphadenopathy was observed in 4% of patients in early stages and in 15% of patients in advanced stages [42].…”

“…In a recent meta analysis regarding CT findings in COVID-19, the time dependence of different CT findings was investigated [42]. Pleural effusion and lymphadenopathy were more frequently identified in later disease stages [42].…”

“…In a recent meta analysis regarding CT findings in COVID-19, the time dependence of different CT findings was investigated [42]. Pleural effusion and lymphadenopathy were more frequently identified in later disease stages [42]. So far, pleural effusion was found in 5% of patients in early stages and in 16% of patients in advanced stages [42].…”

Clinical importance of thoracal lymphadenopathy in COVID-19

“…In a recent meta analysis of CT findings in COVID-19, the time dependence of different CT findings was elucidated [24] . Thoracal lymphadenopathy was more frequently identified in later disease stages with 15% compared to 5% in the early stage [24] .…”